JP2019524690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524690A5 JP2019524690A5 JP2018568951A JP2018568951A JP2019524690A5 JP 2019524690 A5 JP2019524690 A5 JP 2019524690A5 JP 2018568951 A JP2018568951 A JP 2018568951A JP 2018568951 A JP2018568951 A JP 2018568951A JP 2019524690 A5 JP2019524690 A5 JP 2019524690A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- patient
- niraparib
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021212103A JP2022031478A (ja) | 2016-06-29 | 2021-12-27 | 卵巣癌の治療方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356461P | 2016-06-29 | 2016-06-29 | |
| US62/356,461 | 2016-06-29 | ||
| US201662402427P | 2016-09-30 | 2016-09-30 | |
| US62/402,427 | 2016-09-30 | ||
| US201762470141P | 2017-03-10 | 2017-03-10 | |
| US62/470,141 | 2017-03-10 | ||
| PCT/US2017/040039 WO2018005818A1 (en) | 2016-06-29 | 2017-06-29 | Methods of treating ovarian cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021212103A Division JP2022031478A (ja) | 2016-06-29 | 2021-12-27 | 卵巣癌の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524690A JP2019524690A (ja) | 2019-09-05 |
| JP2019524690A5 true JP2019524690A5 (enExample) | 2020-08-13 |
| JP7083760B2 JP7083760B2 (ja) | 2022-06-13 |
Family
ID=60787744
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568951A Active JP7083760B2 (ja) | 2016-06-29 | 2017-06-29 | 卵巣癌の治療方法 |
| JP2021212103A Pending JP2022031478A (ja) | 2016-06-29 | 2021-12-27 | 卵巣癌の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021212103A Pending JP2022031478A (ja) | 2016-06-29 | 2021-12-27 | 卵巣癌の治療方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US12383542B2 (enExample) |
| EP (2) | EP4302835A3 (enExample) |
| JP (2) | JP7083760B2 (enExample) |
| KR (2) | KR20230042136A (enExample) |
| CN (1) | CN109640992A (enExample) |
| AU (1) | AU2017290244B2 (enExample) |
| BR (1) | BR112018077492A2 (enExample) |
| CA (1) | CA3029671C (enExample) |
| DK (1) | DK3478286T3 (enExample) |
| ES (1) | ES2969816T3 (enExample) |
| FI (1) | FI3478286T3 (enExample) |
| HR (1) | HRP20240136T1 (enExample) |
| HU (1) | HUE064978T2 (enExample) |
| IL (1) | IL263925B2 (enExample) |
| LT (1) | LT3478286T (enExample) |
| MX (1) | MX394062B (enExample) |
| NZ (1) | NZ749413A (enExample) |
| PL (1) | PL3478286T3 (enExample) |
| PT (1) | PT3478286T (enExample) |
| RS (1) | RS65180B1 (enExample) |
| SG (1) | SG11201811564QA (enExample) |
| SI (1) | SI3478286T1 (enExample) |
| SM (1) | SMT202400105T1 (enExample) |
| WO (1) | WO2018005818A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| EP3666794A1 (en) | 2016-11-01 | 2020-06-17 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| BR112019008861A2 (pt) | 2016-11-01 | 2019-07-09 | Tesaro, Inc. | anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3) |
| BR112019014187A2 (pt) | 2017-01-09 | 2020-02-11 | Tesaro, Inc. | Métodos de tratamento de câncer com anticorpos anti-pd-1 |
| SG10201913083SA (en) | 2017-01-09 | 2020-03-30 | Tesaro Inc | Methods of treating cancer with anti-tim-3 antibodies |
| EP3600314A1 (en) | 2017-03-27 | 2020-02-05 | Tesaro, Inc. | Niraparib compositions |
| CN118271233A (zh) | 2017-04-24 | 2024-07-02 | 特沙诺有限公司 | 尼拉帕利的制造方法 |
| US12156872B2 (en) * | 2017-05-09 | 2024-12-03 | Tesaro, Inc. | Combination therapies for treating cancer |
| CA3063715A1 (en) | 2017-05-18 | 2018-11-22 | Tesaro, Inc. | Combination therapies for treating cancer |
| CA3076907A1 (en) | 2017-09-26 | 2019-04-04 | Tesaro, Inc. | Niraparib formulations |
| CN111372607A (zh) | 2017-09-30 | 2020-07-03 | 特沙诺有限公司 | 用于治疗癌症的联合疗法 |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| CA3090479A1 (en) * | 2018-02-05 | 2019-08-08 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
| WO2019195443A1 (en) * | 2018-04-04 | 2019-10-10 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor |
| WO2020072796A1 (en) | 2018-10-03 | 2020-04-09 | Tesaro, Inc. | Crystalline forms of niraparib freebase |
| TWI853841B (zh) | 2018-10-03 | 2024-09-01 | 美商提薩羅有限公司 | 尼拉帕尼（niraparib）鹽 |
| EP3857555A4 (en) | 2018-10-17 | 2022-12-21 | Tempus Labs | DATA-BASED CANCER RESEARCH AND TREATMENT SYSTEMS AND PROCEDURES |
| US10395772B1 (en) | 2018-10-17 | 2019-08-27 | Tempus Labs | Mobile supplementation, extraction, and analysis of health records |
| CA3122070A1 (en) | 2018-12-03 | 2020-06-11 | Tempus Labs, Inc. | Clinical concept identification, extraction, and prediction system and related methods |
| JP2022516170A (ja) * | 2019-01-04 | 2022-02-24 | アクティニウム ファーマシューティカルズ インコーポレイテッド | Ｐａｒｐインヒビターおよび抗体放射性物質結合体の組み合わせを使用してがんを処置するための方法 |
| US11705226B2 (en) | 2019-09-19 | 2023-07-18 | Tempus Labs, Inc. | Data based cancer research and treatment systems and methods |
| TW202116316A (zh) * | 2019-07-15 | 2021-05-01 | 美商提薩羅有限公司 | 治療卵巢、輸卵管及腹膜癌之方法 |
| US11295841B2 (en) * | 2019-08-22 | 2022-04-05 | Tempus Labs, Inc. | Unsupervised learning and prediction of lines of therapy from high-dimensional longitudinal medications data |
| WO2021138215A1 (en) * | 2019-12-31 | 2021-07-08 | Kinnate Biopharma Inc. | Treatment of cancer with cdk12/13 inhibitors |
| CA3158900A1 (en) * | 2020-01-13 | 2021-07-22 | John Nemunaitis | Methods for treating cancers using gm-csf encoding polynucleotide and additional agents |
| UY39204A (es) * | 2020-05-08 | 2021-11-30 | Janssen Pharmaceutica Nv | Formulaciones farmacéuticas de acetato de abiraterona y niraparib |
| KR20230113742A (ko) * | 2020-10-29 | 2023-08-01 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 난소암의 검출 및 치료를 위한 방법 |
| KR102858757B1 (ko) | 2022-01-25 | 2025-09-10 | 서울대학교산학협력단 | 상동 재조합 결핍 연관 유전자 도출 장치 및 방법, 상동 재조합 결핍 판단 모델 생성 장치 및 방법과, 상동 재조합 결핍 판단 장치 및 방법 |
| CN119156216A (zh) | 2022-02-15 | 2024-12-17 | 特沙诺有限公司 | 尼拉帕尼用于治疗脑癌的用途 |
| CN115253066A (zh) * | 2022-07-21 | 2022-11-01 | 湖南安泰康成生物科技有限公司 | 卵巢癌治疗系统以及卵巢癌治疗的交变电场发生装置 |
| CN116092631A (zh) * | 2023-01-17 | 2023-05-09 | 湖南安泰康成生物科技有限公司 | 铁死亡诱导剂与电场联用的肿瘤治疗系统 |
| WO2025061057A1 (en) * | 2023-09-19 | 2025-03-27 | Impact Therapeutics (Shanghai) , Inc | Use of a parp inhibitor in maintenance therapy of ovarian cancer |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2647545C (en) | 2006-04-03 | 2016-02-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
| EP2805945B1 (en) | 2007-01-10 | 2019-04-03 | MSD Italia S.r.l. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
| JP5593229B2 (ja) | 2007-10-17 | 2014-09-17 | クドス ファーマシューティカルズ リミテッド | ４−［３−（４−シクロプロパンカルボニル−ピペラジン−１−カルボニル）−４−フルオロ−ベンジル］−２ｈ−フタラジン−１−オン |
| CA2705417A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| US8500933B2 (en) | 2007-12-14 | 2013-08-06 | Guardian Industries Corp. | Localized heating of edge seals for a vacuum insulating glass unit, and/or unitized oven for accomplishing the same |
| JP5989965B2 (ja) | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| EP2237684A2 (en) | 2008-01-08 | 2010-10-13 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| CN102482282A (zh) | 2009-08-26 | 2012-05-30 | 赛福伦公司 | 多环化合物的新形式 |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| WO2011153383A1 (en) | 2010-06-04 | 2011-12-08 | Bipar Science, Inc. | Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound |
| DK2582847T3 (en) | 2010-06-18 | 2016-12-19 | Myriad Genetics Inc | METHODS AND MATERIALS TO ASSESS loss of heterozygosity |
| WO2012027224A1 (en) | 2010-08-24 | 2012-03-01 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| CA2742342A1 (en) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
| CA2779052A1 (en) | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
| WO2013182645A1 (en) | 2012-06-07 | 2013-12-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| WO2014052550A1 (en) * | 2012-09-27 | 2014-04-03 | Thomas Jefferson University | Use of parp inhibitors to treat breast cancer |
| WO2014085698A1 (en) | 2012-11-28 | 2014-06-05 | Sloan-Kettering Institute For Cancer Research | Compositions and methods for the treatment of cancers associated with a deficiency in the mre11/rad50/nbs1 dna damage repair complex |
| US9580407B2 (en) | 2012-12-07 | 2017-02-28 | Merck Sharp & Dohme Corp. | Regioselective N-2 arylation of indazoles |
| US9738915B2 (en) | 2012-12-07 | 2017-08-22 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| US9850542B2 (en) | 2013-03-04 | 2017-12-26 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (HR) deficient cancer |
| EP3693475A1 (en) * | 2013-04-05 | 2020-08-12 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| KR102243062B1 (ko) | 2013-05-02 | 2021-04-21 | 아납티스바이오, 아이엔씨. | 예정된 사멸-1에 대한 항체 |
| JP6663350B2 (ja) | 2014-01-16 | 2020-03-11 | クロヴィス・オンコロジー，インコーポレーテッド | ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用 |
| WO2015119930A1 (en) | 2014-02-04 | 2015-08-13 | Pfizer Inc. | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
| AU2015228860A1 (en) | 2014-03-13 | 2016-09-08 | F. Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
| RU2016142476A (ru) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
| US10238630B2 (en) * | 2014-05-28 | 2019-03-26 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer |
| US20150344968A1 (en) * | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| CN105384695B (zh) * | 2014-08-22 | 2019-12-20 | 四川海思科制药有限公司 | 嘧啶衍生物及其制备方法和在医药上的应用 |
| CN112877426A (zh) | 2014-08-25 | 2021-06-01 | 创新微技术公司 | 在血液中的循环细胞生物标记在检测和诊断疾病中的应用及其分离方法 |
| EP3230472A4 (en) | 2014-12-08 | 2018-06-13 | Myriad Genetics, Inc. | Methods and materials for predicting response to niraparib |
| US20170000885A1 (en) | 2015-06-08 | 2017-01-05 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
| DK3954690T3 (da) | 2015-07-02 | 2023-06-06 | Acerta Pharma Bv | Faste former og formuleringer af (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamid |
| JP2018536700A (ja) | 2015-10-26 | 2018-12-13 | メディヴェイション テクノロジーズ， エルエルシー | Ｐａｒｐ阻害剤を用いる小細胞肺がんの治療 |
| EP3414692A4 (en) | 2016-02-12 | 2020-07-29 | Nantomics, LLC | HIGH-RATE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES |
| WO2017151554A1 (en) * | 2016-02-29 | 2017-09-08 | Synta Pharmaceuticals Corp | Combination therapy for treatment of ovarian cancer |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| MX2019001224A (es) | 2016-07-29 | 2019-06-03 | Janssen Pharmaceutica Nv | Metodos para tratar el cancer de prostata. |
| CN106496187A (zh) | 2016-09-14 | 2017-03-15 | 陕西科技大学 | 一种制备PARP抑制剂Niraparib的合成方法 |
| CN106432055A (zh) | 2016-09-17 | 2017-02-22 | 青岛辰达生物科技有限公司 | 一种尼拉帕布中间体4‑（哌啶‑3‑基）苯胺的制备方法 |
| BR112019020191A2 (pt) | 2017-03-27 | 2020-04-22 | Tesaro Inc | formulações de niraparib |
| EP3600314A1 (en) | 2017-03-27 | 2020-02-05 | Tesaro, Inc. | Niraparib compositions |
| CN118271233A (zh) | 2017-04-24 | 2024-07-02 | 特沙诺有限公司 | 尼拉帕利的制造方法 |
| SG10201913677SA (en) | 2017-04-27 | 2020-03-30 | Tesaro Inc | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| US20200129482A1 (en) | 2017-06-26 | 2020-04-30 | Abbvie Inc. | Treatment of non-small cell lung cancer |
| CA3076907A1 (en) | 2017-09-26 | 2019-04-04 | Tesaro, Inc. | Niraparib formulations |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| EP3731866A1 (en) | 2017-12-27 | 2020-11-04 | Tesaro Inc. | Methods of treating cancer |
| TW202116316A (zh) | 2019-07-15 | 2021-05-01 | 美商提薩羅有限公司 | 治療卵巢、輸卵管及腹膜癌之方法 |
| KR102336493B1 (ko) | 2019-11-22 | 2021-12-07 | 주식회사 메디풀 | 항균탈취 조성물 및 이의 제조방법 |
-
2017
- 2017-06-29 SG SG11201811564QA patent/SG11201811564QA/en unknown
- 2017-06-29 SM SM20240105T patent/SMT202400105T1/it unknown
- 2017-06-29 LT LTEPPCT/US2017/040039T patent/LT3478286T/lt unknown
- 2017-06-29 PL PL17821262.7T patent/PL3478286T3/pl unknown
- 2017-06-29 RS RS20240163A patent/RS65180B1/sr unknown
- 2017-06-29 AU AU2017290244A patent/AU2017290244B2/en active Active
- 2017-06-29 KR KR1020237008762A patent/KR20230042136A/ko not_active Ceased
- 2017-06-29 EP EP23211450.4A patent/EP4302835A3/en active Pending
- 2017-06-29 IL IL263925A patent/IL263925B2/en unknown
- 2017-06-29 HR HRP20240136TT patent/HRP20240136T1/hr unknown
- 2017-06-29 HU HUE17821262A patent/HUE064978T2/hu unknown
- 2017-06-29 BR BR112018077492-8A patent/BR112018077492A2/pt not_active Application Discontinuation
- 2017-06-29 JP JP2018568951A patent/JP7083760B2/ja active Active
- 2017-06-29 NZ NZ749413A patent/NZ749413A/en unknown
- 2017-06-29 EP EP17821262.7A patent/EP3478286B1/en active Active
- 2017-06-29 MX MX2018016193A patent/MX394062B/es unknown
- 2017-06-29 PT PT178212627T patent/PT3478286T/pt unknown
- 2017-06-29 ES ES17821262T patent/ES2969816T3/es active Active
- 2017-06-29 CN CN201780051916.1A patent/CN109640992A/zh active Pending
- 2017-06-29 CA CA3029671A patent/CA3029671C/en active Active
- 2017-06-29 FI FIEP17821262.7T patent/FI3478286T3/fi active
- 2017-06-29 KR KR1020197002633A patent/KR102510996B1/ko active Active
- 2017-06-29 DK DK17821262.7T patent/DK3478286T3/da active
- 2017-06-29 SI SI201731481T patent/SI3478286T1/sl unknown
- 2017-06-29 WO PCT/US2017/040039 patent/WO2018005818A1/en not_active Ceased
-
2018
- 2018-05-22 US US15/986,536 patent/US12383542B2/en active Active
-
2021
- 2021-12-27 JP JP2021212103A patent/JP2022031478A/ja active Pending
-
2022
- 2022-02-24 US US17/652,422 patent/US20220175751A1/en not_active Abandoned
- 2022-02-24 US US17/652,457 patent/US20220395493A1/en not_active Abandoned
- 2022-02-24 US US17/652,443 patent/US20220175752A1/en not_active Abandoned
-
2023
- 2023-09-08 US US18/463,851 patent/US12527780B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524690A5 (enExample) | ||
| FI3478286T3 (fi) | Menetelmiä munasarjasyövän hoitamiseksi | |
| JP2022031478A5 (enExample) | ||
| JP2014530874A5 (enExample) | ||
| MX2024010140A (es) | Nuevos metodos. | |
| JP2016106150A5 (enExample) | ||
| JP2016508134A5 (enExample) | ||
| JP2015500225A5 (enExample) | ||
| JP2016147915A5 (enExample) | ||
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| JP2016528162A5 (enExample) | ||
| MX395482B (es) | Compuestos antiproliferativos y metodos de uso de los mismos | |
| RU2013156378A (ru) | 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-он для применения при лечении аденокистозной карциномы | |
| JP2016536286A5 (enExample) | ||
| JP2015512398A5 (enExample) | ||
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| MX392408B (es) | Tratamiento de cáncer gástrico usando terapias de combinación que comprenden irinotecán liposómico oxaliplatino, 5-fluoruracilo (y leucovorina). | |
| MX382754B (es) | Terapias combinadas para tratar el cancer. | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| JP2019505529A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2016513703A5 (enExample) | ||
| JP2015502926A5 (enExample) | ||
| RU2015145997A (ru) | Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат | |
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer |